Hershey Says GLP-1s Are Driving Higher Gum and Mint Sales

Why It Matters

The trend illustrates how weight‑loss drugs are reshaping confectionery demand, opening a new growth channel for brands that can meet functional‑snack needs.

Key Takeaways

• Ice Breakers sales up 8% in Q1.
• GLP‑1 users report “bad breath,” driving mint demand.
• Hershey’s revenue rose >10% despite stock dip.
• Premium snack sales rise among GLP‑1 drug users.

Pulse Analysis

The surge of GLP‑1 agonists such as Ozempic, Wegovy and Mounjaro has created a ripple effect beyond the pharmaceutical realm. While these drugs are celebrated for their weight‑loss efficacy, a side effect that isn’t listed on official labels—dry mouth and the so‑called “Ozempic breath”—has prompted users to seek quick freshening solutions. This behavioral tweak has turned functional confectionery, especially breath‑freshening gum and mints, into a niche but rapidly expanding category, as consumers look for convenient ways to manage oral discomfort without compromising diet goals.

Hershey’s Ice Breakers line exemplifies how a traditional candy maker can capitalize on this micro‑trend. The company disclosed an 8% quarter‑over‑quarter increase in sales, contributing to a broader revenue uplift of more than 10% in the first quarter. Although the stock fell over 2% on the day of the earnings call, analysts note that the incremental mint and gum revenue offsets softer performance in other segments and signals a resilient demand pipeline. Hershey’s leadership highlighted the “functional snacking tailwinds” narrative, positioning the brand as a responsive player to emerging health‑driven consumer habits.

The implications extend across the confectionery landscape. Swiss chocolatier Lindt reported faster premium chocolate growth among GLP‑1 users, while Magnum’s executives anticipate higher sales of premium, protein‑rich treats. As weight‑loss drugs push consumers to prune low‑quality snacks, brands that offer higher‑margin, health‑adjacent products stand to capture market share. Companies are now evaluating product‑development roadmaps to embed breath‑freshening or protein‑boosting attributes, turning a side effect into a strategic growth lever in the evolving snack ecosystem.